Calcium dependent protein kinases and Malaria: Identification of chemical start point for drug discovery Symposium: Academic Drug Discovery: Challenges.

Slides:



Advertisements
Similar presentations
MALARIA 40% of the world’s population lives in endemic areas
Advertisements

Up date on malaria vaccine
Quality by Design: A Challenge to the Pharma Industry CAMP Member Companies March 2002 CAMP.
Malaria Challenge Introduction to malaria. Malaria is a life threatening disease which is transmitted to humans through the bites of infected female Anopheles.
ABSTRACT Malaria is the most prevalent disease in Asia, Africa, Central and South America. Malaria is a serious, sometimes fatal disease caused by a parasite.
MALARIA History The disease How people get Malaria ( transmission) Symptoms and Diagnosis Treatment Preventive measures Where malaria occurs in the world.
Malaria: A brief introduction provided by Dr Lynn Fischer, a family doctor in Ottawa.
Malaria  Malaria is a vector borne parasitic disease caused by the genus Plasmodium, affecting over 100 countries of the tropical and subtropical regions.
Fighting Malaria with Engineered Symbiotic Bacteria from Vector Mosquitoes Group B05 Asia Hernandez Bridget Larsen Jiangyang Xu Zac Kannan.
 Examination of malarial parasite.  The blood is stained with Wright's stain.  An ordinary blood smear, if parasite are present,they may be easily recognised.
Malaria By: Keri Gregory. What is Malaria??? Malaria is an infectious disease that is cause by a protozoan parasite.
Drug discovery targeting Malaria Protein production and assay development Imperial academic and DDC Target Identification and Validation Imperial College/
A Population Genetics Model of Malaria (Plasmodium berghei) Resistance in the Mosquito Vector Anopheles stephensi Mary Jane Richardson and Leah Sauchyn.
Start on the T/F quiz at your desk…Let’s see what you already know.
Malaria Research Program at CBER Studies to improve Blood Safety from the risk of transfusion- transmitted malaria, and malaria pathogenesis and control.
F INDINGS National Institutes of Health National Institute of General Medical Sciences Science Without Borders Geneticist Dyann Wirth: Understanding the.
A New Treatment for Malaria: Artemisinin Prof. Dr. Talal Aburjai.
1. OUR MISSION To reduce the burden of malaria in disease-endemic countries by discovering, developing and facilitating access of new, effective and affordable.
M ALARIA RESEARCH IN THE POST - GENOMIC ERA Presenter: Reihaneh Rabbany Presented in Bioinformatics Course (CMPUT 606), Instructed by Prof. Guohui Lin,
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Chapter 13. The Impact of Genomics on Antimicrobial Drug Discovery and Toxicology CBBL - Young-sik Sohn-
Seasonal Malaria and Resistance to Chloroquine: Simulations and Maps Joyce Cadwallader, Tony Weisstein, and Margaret Waterman Tool: HEME (Deme 2.3 Plasmodium)
Identification of New Inhibitors of Plasmodium falciparum Enoyl- ACP Reductase Symposium on: Advances in Parasitology “Education and Research in Parasitology.
Synthetically Engineered Artemisinin Lianne Ryan.
The pre-erythrocytic stage, when the parasite is in the hepatocytes MALARIA VACCINES.
“MALARIA” Binding of Malaria Parasites to Host cells Advanced cell biology II, class presentation Kedar Ghimire, April 5, 2006 EM of a plasmodium.
Molecular Interactions Involved In Erythrocyte Invasion By Malaria Parasite Thesis Submitted to Jawaharlal Nehru University for the Award of the Degree.
Characterization of the putative surface protein TLP in Plasmodium berghei and Plasmodium falciparum Ryan M Harrison 1,2, Cristina K Moreria 3, Catherine.
ANALYSIS ANTI-MALARIAL DRUG: COARTEM 20/120 Aaron Beck, Alexis Balgeman, John N. Gitua (Mentor) Department of Chemistry, College of Arts and Sciences Drake.
ChEMBL– Open Access Database For Drug Discovery By – Udghosh Singh M.S.(Pharm), 3 rd Sem Pharmacoinformatics.
Apicomplexa: Plasmodium
Structural Genomics Consortium releases 1,000th protein structure The Structural Genomics Consortium (SGC), an international public-private partnership.
Relative cost of antimalrial drug
Plasmodium & Human Symbiosis By: Rachel Schwab. Evasive Parasite Plasmodium hide in the human liver and in blood cells They hide from the immune system.
MULTIPLE POPULATIONS OF ARTEMISININ-RESISTANT PLASMODIUM FALCIPARUM IN CAMBODIA MIOTTO ET. AL Presented by Josie Benson.
Chapter 22 Malaria: The Challenge of Scaling-Up Multiple Effective Tools.
Malaria is a vector-borne infectious disease caused by protozoan parasites. It is widespread in tropical and subtropical regions, including parts of the.
26th April 2016, BioTrinity - London
신기술 접목에 의한 신약개발의 발전전망과 전략 LGCI 생명과학 기술원. Confidential LGCI Life Science R&D 새 시대 – Post Genomic Era Genome count ‘The genomes of various species including.
Instituto de Medicina Molecular Lisboa, Portugal Miguel Prudêncio New drugs for treating and eradicating malaria.
W HAT IS MALARIA ?  Malaria: disease caused a parasitic protozoan species of the genus Plasmodium  Phylum Apicomplexa (“animal- like” protists)  3.
CATEGORY: PATHOGENS & DISEASE
Copyright © 2017 American Academy of Pediatrics.
PPT ON PLASMODIUM VIVAX ( MALARIAL PARASITE)
Computational Evaluation of 22 identified malaria Drug targets
Copyright © 2017 American Academy of Pediatrics.
Copyright © 2017 American Academy of Pediatrics.
Malaria Research in the Real World
Volume 16, Issue 1, Pages (July 2014)
Plasmodium Life Cycle Mark F. Wiser
Chemical Genetic Modifier Screens
APICOMPLEXA Plasmodium species
Volume 21, Issue 1, Pages (January 2017)
Volume 21, Issue 10, Pages (December 2017)
Volume 8, Issue 4, Pages (October 2010)
8.1 Metabolism Essential idea: Metabolic reactions are regulated in response to the cell’s needs.
Volume 16, Issue 1, Pages (July 2014)
Malaria: New Vaccines for Old?
Pathogenic Protozoa.
Volume 22, Issue 6, Pages e4 (December 2017)
Personalized Medicine: Patient-Predictive Panel Power
(Top) Life cycle of Plasmodium falciparum and gametocyte development.
Pharmacology 3 antimalarial drugs lecture 11 by Prof.Dr. Mohamed Fahmy
Volume 19, Issue 12, Pages (December 2012)
Volume 12, Issue 1, Pages 9-19 (July 2012)
Volume 17, Issue 3, Pages (March 2015)
Calcium-Dependent Signaling and Kinases in Apicomplexan Parasites
Volume 117, Issue 4, Pages (May 2004)
Abebe Genetu Bayih, PhD University of Gondar
Volume 28, Issue 17, Pages e6 (September 2018)
Presentation transcript:

Calcium dependent protein kinases and Malaria: Identification of chemical start point for drug discovery Symposium: Academic Drug Discovery: Challenges and perspectives Imperial College London, March 2011 Oliver Billker & Katie Chapman

Antimalarial drugs No longer useful against P. falciparum Wide spread resistance Artemisinin Chloroquine First-line treatment of P. falciparum Component of a combination. Reduced efficacy observed in SE Asia. Important to develop a well supplied pipeline of new antimalarials.

Antimalarial drug development Antimalarials are not economically attractive to the pharmaceutical industry. Public-private partnerships play a key role. E.g. Medicines for Malaria Venture, Wellcome Trust, Bill & Melinda Gates Foundation Opportunity and need for academic institutions to make an impact.

A paradigm shift in antimalarial screening Cell based screens Libraries of > starting points for drug development Target based screening Genetic tools for target identification at scale (Sanger team) Identify mechanism of induced resistance. Screen against validated targets Prioritise by chemistry, IP, etc.

2 million GSK compounds inhibitors of P. falciparum growth IC 50 < 1 µM 242 inhibitors P. falciparum CDPK 1, 4 or 5 Nature, March 2010

Systematic prioritisation of parasite kinase targets in a malaria parasite of rodents Gene deletion analysis of 65 protein kinases. Kinomes are highly conserved across Plasmodium species. >1/3 of parasite protein kinases are redundant in blood stages.

Comparative analysis of Plasmodium kinomes Different in P. falciparumRedundant in P. berghei Rita Tewari

calmodulin-like domain kinase domain Calcium dependent protein kinases (CDPKs) Plant-like kinases with a unique activation mechanism. Billker & Doerig 2010

Target selection Redundant in P. berghei CamK Plant like  Opportunity for selectivity Family  Opportunity for multi-target inhibitor. CDPK1 and 5: Essential in blood stages. CDPK1 and 4 Essential for transmission.

CDPK5 Predicted CDPK functions CDPK1 CDPK4 CDPK1 CDPK4 CDPK1

Host cell lysis Male gamete formation Differential gene expression Guanlyl cyclase cGMP PKG Phospho- diesterases Map-2 CDPK4 is required for male gamete formation SRPK PKG

Comparative profiling of recombinant PfCDPK1 and 4 unselectiveC1 selectiveC4 selective Katie Chapman, Imperial College Drug Discovery

cdpk4 CDPK4 is required for male gamete formation

DMSO1NM-PP1 DMSO 1NM-PP1 The CDPK4 inhibitor 1NM-PP1 blocks parasite transmission to mosquitoes Lotta Burström

P. berghei CDPK1-GFP is expressed throughout life cycle ookinete gametocytes oocyst sporozoites Sarah Sebastian schizont

cdpk1 knock down blocks development… WT ookinete zygote ookinete retort Sarah Sebastian

, ,000 average oocysts/midgut feed n WT CDPK1 fold change …and prevents transmission of P. berghei to mosquitoes Sarah Sebastian

Target prioritisation: CDPK5 is also essential for blood stage development. Science 238 (2010)

CDPK1, 4 & 5 are individually essential for parasite development at different life cycle stages. Absence of redundancy due to different subcellular localisations (lipid modification), expression patterns, substrate preferences. Pan-CDPK inhibitor could exploit synergies and delay emergence of resistance. Target summary Aim: Screen P. falciparum versions of all three targets to explore feasibility of pan-CDPK inhibition